Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More

Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.

AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod

The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $107.72, marking a +0.61% move from the previous day.

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot

FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.

AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA

AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.

Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.

AbbVie (ABBV) Stock Moves -1.23%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $106.40, moving -1.23% from the previous trading session.

AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $106.48, moving -0.93% from the previous trading session.

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

Kinjel Shah headshot

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Zacks Value Investor Highlights: AbbVie, Chevron, RH, Aon and Kroger

Zacks Value Investor Highlights: AbbVie, Chevron, RH, Aon and Kroger

Tracey Ryniec headshot

Is Berkshire Hathaway Trading in its Stock Portfolio?

If Buffett believes in holding stocks forever, why is Berkshire selling in less than a year?

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $110.36 in the latest trading session, marking a +1.22% move from the prior day.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences

Sheraz Mian headshot

Top Analyst Reports for Facebook, AbbVie & 3M

Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), AbbVie Inc. (ABBV), and 3M Company (MMM).

Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment

The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.

Kinjel Shah headshot

Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates

FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.